Evidence map›Paper›PMID 34590187›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Zoledronic acid-loaded lipidic nanoparticles enhance apoptosis and attenuate invasiveness by inhibiting epithelial to mesenchymal transition (EMT) in HepG

Mehdi Sabzichi, Omolbanin Oladpour, Jamal Mohammadian, Mohsen Rashidi, Mahla Hosseinzadeh, Alireza Mardomi, Bahman Ramezani, Marjan Ghorbani, Fatemeh Ramezani

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Opioid System and Epithelial-Mesenchymal Transition.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Mehdi SabzichiLiver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Omolbanin OladpourDepartment of Immunology, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Jamal MohammadianLiver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Mohsen RashidiDepartment of Pharmacology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Mahla HosseinzadehFaculty of Veterinary Medicine, Tabriz Branch Islamic Azad University, Tabriz, Iran.
Alireza MardomiLiver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Bahman RamezaniDepartment of Chemistry, Tabriz Branch Islamic Azad University, Tabriz, Iran.
Marjan GhorbaniStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Fatemeh RamezaniLiver and Gastrointestinal Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ramezanif@tbzmed.ac.ir.ORCID http://orcid.org/0000-0002-0127-6012

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this study was to evaluate the potential of zoledronic acid (ZOL)-loaded lipidic nanoparticles (ZOL-NLCs) in enhancing the efficiency of paclitaxel (Pac) in the context of cytotoxicity, apoptosis, and invasiveness of HepG

Indexed as

LiposomesNanoparticlesAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarcinoma, HepatocellularCell MovementEpithelial-Mesenchymal TransitionHep G2 CellsHumansInhibitory Concentration 50Liver NeoplasmsNeoplasm InvasivenessPaclitaxelZoledronic AcidLipid NanoparticlesLiposomesPaclitaxelZoledronic AcidApoptosisInvasivenessNanoparticlesZoledronic acid

Identifiers

PMID34590187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.